Antibody-based therapies for COVID-19: Can Europe move faster? | PLOS Medicine Skip to
main content Advertisement PLOS Medicine Browse Current Issue Journal Archive Special …

Background As the global COVID-19 pandemic reaches its 2nd year, over 270 million cases
and 5.3 million deaths have occurred globally. Nearly, 3000 clinical trials have been …

COVID-19 is an acute respiratory syndrome caused by SARS-COV-2 which has now
become a huge pandemic worldwide. The immunopathogenesis of COVID-19 has been …

Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …

The medical care of immunocompromised patients with COVID-19 infection causes major
hurdles in the management of these patients in clinical practice. However, poor responses to …

The global pandemic of COVID-19 is currently ongoing [1]. To date, pharmacological agents
used to treat patients with COVID-19 have been directed at avoiding and reducing the …

The COVID-19 pandemic continues to cause tremendous loss of life and put massive strain
on the functioning of societies worldwide. Despite the cataclysmic proportions of this viral …

Introduction. When a new disease occurs, one of the most affordable remedies is drugs
containing specific antibodies to this infectious agent. The use of such drugs is aimed at …

The current COVID-19 global pandemic poses immense challenges to global health, largely
due to the difficulty to detect infection in the early stages of the disease, as well as the …

The harmful COVID-19 pandemic caused by the SARS-CoV-2 coronavirus imposes the
scientific community to develop or find conventional curative drugs, protective vaccines, or …